Gil M. Labrucherie was appointed to a dual role as Chief Operating Officer and Chief Financial Officer of the company in October 2019. In this role, Mr. Labrucherie oversees business operations, quality assurance, business development, finance, supply chain logistics and information technology functions for the company. Mr. Labrucherie has held several senior leadership positions with increasing responsibility at Nektar since 2005.
Prior to joining Nektar, from October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open, Inc., where he was responsible for global corporate alliances and merger and acquisition activity. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for merger and acquisition transactions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati.
Mr. Labrucherie received his J.D. from University of California Berkeley, School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis.
What is Gil M. Labrucherie's net worth?
The estimated net worth of Gil M. Labrucherie is at least $29,083.65 as of February 25th, 2025. Mr. Labrucherie owns 36,282 shares of Nektar Therapeutics stock worth more than $29,084 as of March 27th. This net worth estimate does not reflect any other investments that Mr. Labrucherie may own. Learn More about Gil M. Labrucherie's net worth.
How do I contact Gil M. Labrucherie?
The corporate mailing address for Mr. Labrucherie and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at investors@nektar.com. Learn More on Gil M. Labrucherie's contact information.
Has Gil M. Labrucherie been buying or selling shares of Nektar Therapeutics?
Gil M. Labrucherie has not been actively trading shares of Nektar Therapeutics over the course of the past ninety days. Most recently, Gil M. Labrucherie sold 17,448 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $3.95, for a transaction totalling $68,919.60. Following the completion of the sale, the chief financial officer now directly owns 312,905 shares of the company's stock, valued at $1,235,974.75. Learn More on Gil M. Labrucherie's trading history.
Who are Nektar Therapeutics' active insiders?
Are insiders buying or selling shares of Nektar Therapeutics?
During the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 310,901 shares worth more than $377,218.13. The most recent insider tranaction occured on February, 19th when insider Jonathan Zalevsky sold 10,300 shares worth more than $10,403.00. Insiders at Nektar Therapeutics own 3.7% of the company.
Learn More about insider trades at Nektar Therapeutics. Information on this page was last updated on 2/19/2025.
